I hope this transcript serves as a valuable source of information for the report you are preparing. The company's recent earnings call shows strong financial results for the fourth quarter of fiscal 2017. Key points to highlight include the company's solid revenue growth, especially in international sales, the strong performance of the Diagnostics and Breast Health divisions, and the potential for growth in the Medical Aesthetics division. It is clear that the company is making significant progress in building a sustainable growth company with a focus on long-term growth. These factors indicate that an 'overweight' investment stance would be a favorable recommendation for potential investors.